ABSCI CORP
ABSINASDAQTrading Snapshot
- Day Range
- $9.31 – $9.45
- 52-Week Range
- $2.24 – $12.06
- Volume
- $6.84B
- Avg Volume
- $8.85B
- Shares Outstanding
- 169.4M
- Next Earnings
- Sep 21, 2026
Fundamentals Snapshot
- Annual Revenue
- $3M
- Last Q Revenue
- $711,058
- P/E Ratio
- -11.8
- P/S Ratio
- 1282.4x
- EPS (TTM)
- $-0.77
- Dividend Yield
- 0.00%
Why Investors Own ABSI
- ✓High-growth profile — revenue up +4.8% YoY with expanding US Equity exposure.
- ✓Healthy economics — 27% gross margin and 17% free-cash-flow margin.
- ✓New products and segments could unlock additional revenue streams.
Execution delays, intensifying competition, and valuation compression if growth decelerates.
Financial Trends
About ABSCI CORP
Absci Corporation operates as a biopharmaceutical company primarily focused on discovering novel drug targets and developing new therapeutic compounds. Leveraging its distinctive integrated drug creation platform, the firm generates potential biologic medicines and essential cell lines for manufacturing, which it provides to its collaborators, predominantly within the United States. This advanced platform is instrumental in facilitating the development of biologics by meticulously integrating the traditionally separate stages of drug discovery and cell line engineering into one streamlined process. Absci Corporation was founded in 2011 and is based in Vancouver, Washington.
Otter Score Breakdown
ⓘAnalyst Price Target
ⓘLatest News & Updates
ABSCI CORP tops quarterly estimates as demand accelerates
Revenue grew double digits with management guiding above consensus; margins continued to expand.
Analysts lift ABSI price targets on improving margins
Several firms raised targets, citing stronger free cash flow and a healthier backlog.
ABSCI CORP announces new agreement to expand its footprint
The move broadens the company’s reach and could add incremental revenue over the next year.